Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Alter (2002)
Prevention of spread of hepatitis CHepatology, 36
R. Haley, R. Fischer (2001)
Commercial Tattooing as a Potentially Important Source of Hepatitis C Infection: Clinical Epidemiology of 626 Consecutive Patients Unaware of Their Hepatitis C Serologic StatusMedicine, 80
G. Schreiber, M. Busch, S. Kleinman, J. Korelitz (1996)
The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.The New England journal of medicine, 334 26
R. Gunn, P. Murray, D. Callahan, M. Alter, H. Margolis (2003)
Evaluation of Screening Criteria to Identify Persons With Hepatitis C Virus Infection Among Sexually Transmitted Disease Clinic Clients: Results From The San Diego Viral Hepatitis Integration ProjectSexually Transmitted Diseases, 30
Alter Alter, Gerety Gerety, Smallwood Smallwood (1982)
Sporadic non A, non B hepatitis: frequency and epidemiology in an urban United States populationJ Infect Dis, 145
R. Dodd, E. Notari, S. Stramer (2002)
Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor populationTransfusion, 42
G. Willis (1997)
The use of the psychological laboratory to study sensitive survey topics.NIDA research monograph, 167
Elise Beltrami, A. Kozak, I. Williams, A. Saekhou, M. Kalish, O. Nainan, S. Stramer, Mei-Chen Fucci, D. Frederickson, D. Cardo (2003)
Transmission of HIV and hepatitis C virus from a nursing home patient to a health care worker.American journal of infection control, 31 3
(1994)
The cognitive aspects of responses to sensitive survey questions
M. Alter, R. Gerety, L. Smallwood, R. Sampliner, E. Tabor, F. Deinhardt, G. Frösner, G. Matanoski (1982)
Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population.The Journal of infectious diseases, 145 6
F. Caredda, S. Antinori, C. Pastecchia, P. Coppin, M. Moroni (1988)
SPORADIC NON-A, NON-B HEPATITISThe Lancet, 331
(2000)
- transmitted diseases : Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors
Durand (2000)
Evidence of hepatitis C viremia without detectable antibody to hepatitis C virus in a blood donorAnn Intern Med, 133
M. Alter, S. Hadler, F. Judson, A. Mares, W. Alexander, Pindiga Hu, Joan Miller, L. Moyer, H. Fields, D. Bradley, H. Margolis (1990)
Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection.JAMA, 264 17
C. Conry-Cantilena, M. Vanraden, J. Gibble, J. Melpolder, A. Shakil, L. Viladomiu, L. Cheung, A. Dibisceglie, J. Hoofnagle, J. Shih, R. Kaslow, P. Ness, H. Alter (1996)
Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.The New England journal of medicine, 334 26
(2002)
Prevention of spread of hepatitis
Williams (1997)
Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor StudyJ Am Med Assoc, 277
(2002)
Hepatitis C virus RNA concentration and chronic hepatitis in a cohort of patients followed after developing acute hepatitis C
S. Moore, J. Kruger, J. Rakela, E. Vamvakas, C. Schimek, J. Germer, D. Persing (1995)
Blood donors who are repeatedly reactive for hepatitis C virus on enzyme immunoassay and positive on recombinant immunoblot assay: evidence of failure to identify some risk factorsTransfusion, 35
(2003)
Virus from a nursing home patient to a health care worker
G. Schreiber, M. Busch, S. Kleinman, J. Korelitz (1996)
The Risk of Transfusion-Transmitted Viral InfectionsThe New England Journal of Medicine, 334
Girish Mishra, C. Sninsky, R. Roswell, S. Fitzwilliam, K. Hyams (2003)
Risk Factors for Hepatitis C Virus Infection Among Patients Receiving Health Care in a Department of Veterans Affairs HospitalDigestive Diseases and Sciences, 48
B. Larke, Yu-Wen Hu, M. Krajden, V. Scalia, Sean K. Byrne, L. Boychuk, Judith Klein (2002)
Acute nosocomial HCV infection detected by NAT of a regular blood donorTransfusion, 42
C. Conry-Cantilena, J. Melpolder, H. Alter, J. Gorlin, K. Mascotti (1998)
Intranasal drug use among volunteer whole‐blood donors: results of Survey CTransfusion, 38
(2000)
Long-Term Prevention of Bone Loss
A. Williams, R. Thomson, George Schreiber, Kevin Watanabe, J. Bethel, Annie Lo, S. Kleinman, C. Hollingsworth, G. Nemo (1997)
Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study.JAMA, 277 12
(2000)
Nucleic acid amplification testing of blood donors for transfusion-transmitted diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors
M. Chamberland, L. Petersen, V. Munn, C. White, E. Johnson, M. Busch, A. Grindon, H. Kamel, P. Ness, A. Shafer, G. Zeger (1994)
Human Immunodeficiency Virus Infection among Health Care Workers Who Donate BloodAnnals of Internal Medicine, 121
N. Terrault (2002)
Sexual activity as a risk factor for hepatitis CHepatology, 36
M. Busch, S. Kleinman, B. Jackson, S. Stramer, I. Hewlett, S. Preston (2000)
Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors.Transfusion, 40 2
E. Murphy, S. Bryzman, S. Glynn, D. Ameti, R. Thomson, A. Williams, C. Nass, H. Ownby, G. Schreiber, F. Kong, K. Neal, G. Nemo (2000)
Risk factors for hepatitis C virus infection in United States blood donorsHepatology, 31
BACKGROUND: In 1999, NAT of blood donations was implemented to detect “window‐period” infections. Blood donors who have confirmed NAT results positive for the presence of HCV in the absence of anti‐HCV are likely to have been recently infected. Of over 26.8 million donations tested between March 3, 1999, and March 31, 2003, 810 were HCV‐reactive by NAT. A subset of these donors was assessed for recent exposure risk. STUDY DESIGN AND METHODS: All anti‐HCV– blood donors with reactive, unconfirmed HCV NAT results were invited to participate in a study that included an extensive demographic and risk questionnaire. Confirmed HCV+ cases were compared to HCV– (falsely positive) controls for histories of potential risk factors during the 6 months before donation. RESULTS: Recent injection drug use (IDU) was independently associated with HCV infection (29.2% vs. 0% of cases vs. controls, p < 0.001). In addition, likely sources were identified for three other cases (4.6%), including occupational exposure, sexual contact with an HCV‐infected partner (who was an IDU), and perinatal exposure, none of which was known to the donors at the time of donation. Incarceration was independently associated with HCV infection among the group not reporting IDU and after removal of the three donors with likely sources of risk (14.6% vs. 1.3% of cases vs. controls, p < 0.001). CONCLUSIONS: A likely risk, primarily IDU, was found for 43 percent of HCV+ donors whose infections were identified solely by NAT. Because the maximum efficiency of the donor history questions may have been reached, NAT will continue to be an important measure to interdict recently infected blood donors.
Transfusion – Wiley
Published: Feb 1, 2004
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.